CN112867496B - 用于治疗神经退行性疾病的基于car-treg的疗法 - Google Patents

用于治疗神经退行性疾病的基于car-treg的疗法

Info

Publication number
CN112867496B
CN112867496B CN201980035934.XA CN201980035934A CN112867496B CN 112867496 B CN112867496 B CN 112867496B CN 201980035934 A CN201980035934 A CN 201980035934A CN 112867496 B CN112867496 B CN 112867496B
Authority
CN
China
Prior art keywords
ser
gly
thr
cells
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201980035934.XA
Other languages
English (en)
Chinese (zh)
Other versions
CN112867496A (zh
Inventor
菲利普·G·艾什顿-里卡德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Aztherapies Inc
Original Assignee
Smith Treatment Co
Aztherapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Treatment Co, Aztherapies Inc filed Critical Smith Treatment Co
Publication of CN112867496A publication Critical patent/CN112867496A/zh
Application granted granted Critical
Publication of CN112867496B publication Critical patent/CN112867496B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/414—Nervous system antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/10—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the structure of the chimeric antigen receptor [CAR]
    • A61K2239/11—Antigen recognition domain
    • A61K2239/13—Antibody-based
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Psychiatry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Psychology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
CN201980035934.XA 2018-03-27 2019-03-21 用于治疗神经退行性疾病的基于car-treg的疗法 Active CN112867496B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862648684P 2018-03-27 2018-03-27
US62/648,684 2018-03-27
PCT/US2019/023395 WO2019190879A1 (en) 2018-03-27 2019-03-21 Car-treg-based therapies for treating neurodegenerative diseases

Publications (2)

Publication Number Publication Date
CN112867496A CN112867496A (zh) 2021-05-28
CN112867496B true CN112867496B (zh) 2026-03-17

Family

ID=68060734

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980035934.XA Active CN112867496B (zh) 2018-03-27 2019-03-21 用于治疗神经退行性疾病的基于car-treg的疗法

Country Status (7)

Country Link
US (2) US12173030B2 (https=)
EP (1) EP3773629A4 (https=)
JP (3) JP2021531280A (https=)
KR (2) KR102892999B1 (https=)
CN (1) CN112867496B (https=)
AU (1) AU2019242381B2 (https=)
WO (1) WO2019190879A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112867496B (zh) * 2018-03-27 2026-03-17 阿尔茨治疗方法公司 用于治疗神经退行性疾病的基于car-treg的疗法
JP7821119B2 (ja) 2020-04-23 2026-02-26 エーゼットセラピーズ， インコーポレイテッド Ｈｌａクラスｉ ｍｈｃの細胞切除
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
EP4396216A1 (en) * 2021-09-03 2024-07-10 Sangamo Therapeutics, Inc. Mog-binding proteins and uses thereof
TW202321286A (zh) * 2021-09-21 2023-06-01 英商圭爾醫療有限公司 抗p75ntr嵌合抗原受體
GB202113674D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
GB202113673D0 (en) 2021-09-24 2021-11-10 Reflection Therapeutics Ltd Targeted cell therapies
CN118272314A (zh) * 2024-04-15 2024-07-02 华中科技大学同济医学院附属同济医院 一种具有良好血脑屏障通透性的car-t细胞、产品及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140971A2 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Cell adhesion proteins as biomarker for alzheimer's disease
WO2017100428A1 (en) * 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080027001A1 (en) 2006-07-07 2008-01-31 Andrew Wood Nogo receptor functional motifs, peptide mimetics, and mutated functional motifs related thereto, and methods of using the same
US8790642B2 (en) * 2008-08-29 2014-07-29 Genentech, Inc. Cross-reactive and bispecific anti-IL-17A/F antibodies
SG193023A1 (en) * 2011-02-11 2013-10-30 Sloan Kettering Inst Cancer Hla-restricted, peptide-specific antigen binding proteins
KR20140071277A (ko) 2011-05-19 2014-06-11 타이제닉스, 에스.에이.유. 면역조절 활성을 갖는 세포 집단, 그의 제조 방법 및 용도
CN103965357B (zh) * 2013-12-31 2016-08-17 嘉和生物药业有限公司 一种抗人rankl抗体
SG10202013095YA (en) * 2014-12-30 2021-02-25 Brigham & Womens Hospital Inc Methods to improve cell therapy
US20180117171A1 (en) * 2015-04-01 2018-05-03 President And Fellows Of Harvard College Immunoconjugates for programming or reprogramming of cells
CN107708733B (zh) * 2015-04-07 2022-11-15 艾利妥 抗分拣蛋白抗体和其使用方法
EP4321649B1 (en) * 2017-11-11 2025-08-20 Micromaterials LLC Gas delivery system for high pressure processing chamber
CN112867496B (zh) * 2018-03-27 2026-03-17 阿尔茨治疗方法公司 用于治疗神经退行性疾病的基于car-treg的疗法
US20230210899A1 (en) * 2020-05-28 2023-07-06 Aztherapies, Inc. CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007140971A2 (en) * 2006-06-06 2007-12-13 F. Hoffmann-La Roche Ag Cell adhesion proteins as biomarker for alzheimer's disease
WO2017100428A1 (en) * 2015-12-09 2017-06-15 Memorial Sloan Kettering Cancer Center Immune cell compositions and methods of using same

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CAR-T Regulatory （CAR-Treg） Cells：Engineering and Application;Motahareh Arjomandnejad等;Biomedicines;20220126;第10卷(第2期);第1-21页 *
嵌合抗原受体T细胞免疫治疗在自身免疫病的研究进展;王鹏程等;肾脏病与透析肾移植杂志;20191228;第28卷(第6期);第550-555页 *

Also Published As

Publication number Publication date
JP2021531280A (ja) 2021-11-18
KR20210135921A (ko) 2021-11-16
US20250129158A1 (en) 2025-04-24
CA3095298A1 (en) 2019-10-03
JP2025123315A (ja) 2025-08-22
AU2019242381A1 (en) 2020-11-19
EP3773629A4 (en) 2022-01-19
WO2019190879A1 (en) 2019-10-03
KR102892999B1 (ko) 2025-11-28
CN112867496A (zh) 2021-05-28
AU2019242381B2 (en) 2025-04-24
KR20250174989A (ko) 2025-12-15
EP3773629A1 (en) 2021-02-17
US12173030B2 (en) 2024-12-24
JP2024086870A (ja) 2024-06-28
JP7697096B2 (ja) 2025-06-23
US20210023137A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
CN112867496B (zh) 用于治疗神经退行性疾病的基于car-treg的疗法
Zhang et al. Stable intracerebral transplantation of neural stem cells for the treatment of paralysis due to ischemic stroke
JP6748157B2 (ja) 抗上皮成長因子受容体変異体ｉｉｉキメラ抗原受容体及び癌の治療のためのその使用
US8389016B2 (en) Use of a CD28 binding substance for making a pharmaceutical composition
EP4610654A2 (en) Conjugated antibody or bispecific t-cell engager which selectively binds either tcr beta constant region 1 (trbc1) or trbc2
AU2018250336A1 (en) Engineered cells expressing prostate-specific membrane antigen (PSMA) or a modified form thereof and related methods
SA515360253B1 (ar) أجسام مضادة مُميزة لألفا سينوكلين
CN115175935A (zh) Cal-t构建体及其用途
EA030796B1 (ru) Применение связывающих семафорин-4d молекул для промотирования нейрогенеза после инсульта
AU2021392655A9 (en) Methods and materials for treating t cell cancers
US20230210899A1 (en) CAR-Treg-Based Therapies Targeting Myelin Oligodendrocyte Glycoprotein (MOG) for Treating Neurodegenerative Diseases
JP2023551291A (ja) 免疫チェックポイント分子で機能化された改変細胞及びその使用
CA3095298C (en) Car-treg-based therapies for treating neurodegenerative diseases
KR20070007291A (ko) 면역 반응을 유도하거나 조절하는 방법
HK40122801A (zh) 用於治疗神经变性疾病的靶向髓鞘少突胶质细胞糖蛋白(mog)的基於car-treg的疗法
HK40099093A (zh) 用於治疗神经变性疾病的靶向髓鞘少突胶质细胞糖蛋白(mog)的基於car-treg的疗法
US20170198026A1 (en) Compositions And Methods For Treating Tumors And Immune Based Inflammatory Diseases
TW202602496A (zh) 抗ｈａ－１及抗ｈａ－２結合蛋白用於治療ａｍｌ、ａｌｌ及ｍｄｓ之用途
HK40005995B (en) Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
HK40005995A (en) Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer
Matarese et al. Tolerance and autoimmunity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
TA01 Transfer of patent application right

Effective date of registration: 20210601

Address after: Massachusetts, USA

Applicant after: AZTherapies, Inc.

Address before: Massachusetts, USA

Applicant before: Smith treatment Co.

TA01 Transfer of patent application right
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant